Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has warned the people that the anti-seizure drug, Potiga, developed by Valeant Pharmaceuticals and co-marketed with GlaxoSmithKline, may cause eye and skin problems.
Subscribe to our email newsletter
FDA warned that Potiga may cause bluish skin predominantly around lips, fingers and toes and pigment changes in the retina, which may lead to loss of vision.
GlaxoSmithKline spokeswoman Sarah Alspach said that the company informed clinical trial investigators and regulators including the FDA of a new adverse drug reaction which is discoloration of nails, lips and skin.
The FDA has advised that all the patients taking Potiga should have a baseline eye exam, followed by periodic eye exams.
In June 2011, Potiga was approved for the treatment of partial seizures, a type of seizure in people with epilepsy.